Biology subjects

Payami, H.

Publications and source records attributed to Payami, H..

5 recordsLinked to original sources

bioRxiv2026

Elucidating the dysbiotic features of gut microbiome, interaction with the human genome, and utility as a biomarker for treatment of Parkinson disease.

Parkinsons disease (PD) is the fastest-growing neurologic disease and a leading cause of disability worldwide. PD affects the body and mind, is progressive, and there is no prevention or cure. Gut microbiome, a recently recognized contributing factor in PD, offers new leads for understanding the underlying pathobiology and devising new treatments. Here, we present the most comprehensive study of the PD gut microbiome to date, comprising three large datasets with a sample size of 1,006 PD and 544 neurologically healthy controls, generated with uniform methodology from subject recruitment to data analysis, and characterized using deep shotgun metagenome sequencing, genome-wide genotypes, and metadata. We begin by describing the gut dysbiosis at the species, gene, pathway, and functional level. Next, we find that PD-associated genetic variants at the SNCA gene region are associated with increased abundance of opportunistic pathogens and depletion of fiber degraders in the PD gut. We show that the presence of opportunistic pathogens at high levels in the gut increases the penetrance of SNCA variants for PD risk, raising the GWAS-derived odds ratio from less than 1.5 to over 8. The genetic variants identified here control splicing of the SNCA transcripts into alpha-synuclein isoforms with varying affinity for pathological aggregation. These data suggest pathogens are triggers for disease in the setting of genetic susceptibility, and the link to the genome implicates the microbes in the causation of PD. Finally, shifting focus to translation, we show that not all PD patients have the same dysbiotic features, and propose a conceptual framework to identify microbiome-based biomarkers to select appropriate patients for targeted microbiome-based clinical trials and personalized treatment.

molecular biology↗

bioRxiv2024

Alpha-synuclein overexpression can drive microbiome dysbiosis in mice

Growing evidence indicates that persons living with Parkinson disease (PD), have a unique composition of indigenous gut microbes. Given the long prodromal or pre-diagnosed period, longitudinal studies of the human and rodent gut microbiome prior to symptomatic onset and for the duration of the disease period are currently lacking. PD is characterized in part by accumulation of the protein -synuclein (-syn) into insoluble aggregates, in both the central and enteric nervous systems. As such, a number of experimental rodent and non-human primate models of -syn overexpression recapitulate some of hallmark pathophysiologies of PD. These animal models provide an opportunity to assess how the gut microbiome changes with age under disease relevant conditions. Here, we used a transgenic mouse strain, the Thy1-hSYN "line 61" mice which over express wild-type human -syn to test how the gut microbiome composition responds in this model of PD pathology during aging. Using shotgun metagenomics, we find significant, age and genotype dependent bacterial taxa that become altered over age. We reveal that -syn overexpression can drive alterations to the gut microbiome composition and suggest that it limits the expansion of diversity through age. Given emerging data on potential contributions of the gut microbiome to PD pathologies, our data provide an experimental foundation to understand how the PD-associated microbiome may arise as a trigger or co-pathology to disease.

microbiology↗

bioRxiv2022

Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms

Parkinsons disease (PD) may start in the gut and spread to the brain. To investigate the role of gut microbiome, we enrolled 490 PD and 234 control individuals, conducted deep shotgun sequencing of fecal DNA, followed by metagenome-wide association studies requiring significance by two methods (ANCOM-BC and MaAsLin2) to declare disease association. Thirty-percent of species and pathways tested had altered abundances in PD, depicting a widespread dysbiosis. Network analysis showed PD-associated species form polymicrobial clusters that grow or shrink together, and some compete. Metagenomic profile of PD indicates a disease permissive microbiome, evidenced by overabundance of pathogens and immunogenic components, dysregulated neuroactive signaling, preponderance of molecules that induce alpha-synuclein pathology, and over-production of toxicants; with the reduction in anti-inflammatory and neuroprotective factors limiting the capacity to recover. These data provide a broad foundation with a wealth of concrete testable hypotheses to discern the role of the gut microbiome in PD.

genomics↗

bioRxiv2021

Human-genome gut-microbiome interaction in Parkinson's disease

The causes of complex diseases remain an enigma despite decades of epidemiologic research on environmental risks and genome-wide studies that have uncovered tens or hundreds of susceptibility loci for each disease. We hypothesize that the microbiome is the missing link. Genetic studies have shown that overexpression of alpha-synuclein, a key pathological protein in Parkinsons disease (PD), can cause familial PD and variants at alpha-synuclein locus confer risk of idiopathic PD. Recently, dysbiosis of gut microbiome in PD was identified: altered abundances of three microbial clusters were found, one of which was composed of opportunistic pathogens. Using two large datasets, we show that the overabundance of opportunistic pathogens in PD gut is influenced by the host genotype at the alpha-synuclein locus, and that the variants responsible modulate alpha-synuclein expression. This is the first demonstration of interaction between genetic factors in the human genome and the dysbiosis of gut microbiome in PD.

genetics↗

bioRxiv2020

Characterizing dysbiosis of gut microbiome in PD: Evidence for overabundance of opportunistic pathogens

In Parkinsons disease (PD), gastrointestinal features are common and often precede the motor signs. Braak and colleagues proposed that PD may start in the gut, triggered by a pathogen, and spread to the brain. Numerous studies have examined the gut microbiome in PD, all found it to be altered, but found inconsistent results on associated microorganisms. Studies to date have been small (N=20 to 306) and are difficult to compare or combine due to varied methodology. We conducted a microbiome-wide association study (MWAS) with two large datasets for internal replication (N=333 and 507). We used uniform methodology when possible, interrogated confounders, and applied two statistical tests for concordance, followed by correlation network analysis to infer interactions. Fifteen genera were associated with PD at a microbiome-wide significance level, in both datasets, with both methods, with or without covariate adjustment. The associations were not independent, rather represented 3 clusters of co-occurring microorganisms. Cluster 1 was composed of opportunistic pathogens; all were elevated in PD. Cluster 2 were short-chain-fatty-acid producing bacteria; all were reduced in PD. Cluster 3 were carbohydrate-metabolizing probiotics; elevated in PD. Depletion of anti-inflammatory short-chain-fatty-acid producing bacteria and elevated levels of probiotics are confirmatory. Overabundance of opportunistic pathogens is a novel finding and their identity provides a lead to experimentally test their role in PD.

genomics↗